SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject8/22/2001 4:05:07 AM
From: nigel bates   of 625
 
MELBOURN, England, Aug. 22 /PRNewswire/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) today announced the early results from a Phase II clinical trial using CAT-152 (lerdelimumab; human anti-TGFBeta(2) monoclonal antibody) in patients undergoing surgery for glaucoma. CAT-152 has been designed to prevent excessive post-operative scarring which is the major reason why glaucoma surgery can fail to lower intraocular pressure in the long term.
The Phase II clinical trial studied 56 patients who were undergoing combined glaucoma and cataract surgery. Patients were randomized to receive either CAT-152 (36 patients) or matching placebo (20 patients) in a series of four subconjunctival injections which were given on the day of surgery (both immediately pre and post-operatively), the day after surgery and a week after surgery. The primary objective of the trial was to assess safety and tolerability of CAT-152 injection in this group of patients. A secondary objective was demonstration of efficacy of CAT-152.
CAT-152 was found to be safe and well tolerated in this trial with no serious drug-related adverse events and no severe injection site reactions reported. There was no evidence of increased inflammation in the anterior chamber of the eye.
Intraocular pressure (IOP) was successfully lowered by surgery in both patient groups. Three months after operation the achieved IOP was lower in patients receiving CAT-152 (mean value 14.7 mmHg) compared to those receiving placebo (mean value 15.5 mmHg). IOP of 22 mmHg or lower was achieved by 100% of CAT-152 treated patients compared to 17 of 20 (85%) of placebo treated patients. IOP of 18 mmHg or lower was achieved by 31 of 36 (86%) of CAT-152 treated patients compared to 14 of 20 (70%) of placebo treated patients. Pharmacological intervention (5FU injection or topical IOP lowering medication) was used in 10 of 36 (28%) of CAT-152 treated patients compared to 4 of 20 (20%) of placebo treated patients. The differences between groups were not statistically significant.
The results of this trial have been accepted for presentation at the American Academy of Ophthalmology in New Orleans, November 2001 at which time six months follow up data will be available.
Commenting on the results, Dr David Glover, CAT's Medical Director said, ``These are early results. The safety data more than justifies proceeding with further clinical trials. We will be following up these combined glaucoma and cataract surgery patients for up to 3 years post operatively. The next CAT-152 clinical trial (Phase II/III) will be in simple glaucoma surgery -- not combined with cataract surgery. We expect that trial to enroll around 350 patients in six European countries and to start in the fourth quarter of this year.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News